Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
about
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastomaMolecular mechanisms in multiple myeloma drug resistanceHSP90 and HSP70: Implication in Inflammation Processes and Therapeutic Approaches for Myeloproliferative NeoplasmsDangER: protein ovERload. Targeting protein degradation to treat myelomaContribution of chaperones to STAT pathway signaling.The co-chaperone Hch1 regulates Hsp90 function differently than its homologue Aha1 and confers sensitivity to yeast to the Hsp90 inhibitor NVP-AUY922Hsp90 inhibitors are efficacious against Kaposi Sarcoma by enhancing the degradation of the essential viral gene LANA, of the viral co-receptor EphA2 as well as other client proteinsThe HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damageGenetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibitionSynthesis, characterization, and pharmacological evaluation of novel azolo- and azinothiazinones containing 2,4-dihydroxyphenyl substituent as anticancer agents.Tanespimycin with bortezomib: activity in relapsed/refractory patients with multiple myeloma.Phase I study of KW-2478, a novel Hsp90 inhibitor, in patients with B-cell malignancies.A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancerHeat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells.Targeting HSP90 and monoclonal protein trafficking modulates the unfolded protein response, chaperone regulation and apoptosis in myeloma cells.Novel therapeutic strategies in multiple myeloma: role of the heat shock protein inhibitors.Inhibition of heat shock protein 90 (HSP90) as a therapeutic strategy for the treatment of myeloma and other cancers.Cancer stem cells, microRNAs, and therapeutic strategies including natural products.Molecular mechanisms of effectiveness of novel therapies in multiple myeloma.Experimental approaches in the treatment of multiple myeloma.HSP90: chaperone-me-not.Heat shock protein 90 and role of its chemical inhibitors in treatment of hematologic malignanciesHeat shock proteins in multiple myelomaUnderstanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back.Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?CD20-targeting in B-cell malignancies: novel prospects for antibodies and combination therapies.Potent antitumor activity of the novel HSP90 inhibitors AUY922 and HSP990 in neuroendocrine carcinoid cells.Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.The novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell cycle arrest and apoptosis in multiple myeloma cells and acts synergistically with melphalan by increased cleavage of caspases.Antitumor activity of NVP-AUY922, a novel heat shock protein 90 inhibitor, in human gastric cancer cells is mediated through proteasomal degradation of client proteins.Combined effects of novel heat shock protein 90 inhibitor NVP-AUY922 and nilotinib in a random mutagenesis screen.Antileukemic activity of the HSP70 inhibitor pifithrin-μ in acute leukemia.The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma.The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells.Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells.Heat shock protein 90 inhibitors induce functional inhibition of human natural killer cells in a dose-dependent manner.The heat shock transcription factor 1 as a potential new therapeutic target in multiple myeloma.Inhibition of focal adhesion kinase overcomes resistance of mantle cell lymphoma to ibrutinib in the bone marrow microenvironment.Phase 1/1B trial of the heat shock protein 90 inhibitor NVP-AUY922 as monotherapy or in combination with bortezomib in patients with relapsed or refractory multiple myeloma.
P2860
Q24607424-41248B5F-4A3E-42C1-A4F2-7990BE4BB500Q26776386-4780F1CC-281E-4D71-8C83-3D5B4CA1D3B8Q26778548-CF4EA863-6CB2-429B-B707-7F4037821E9CQ26825417-F6529572-1A65-4D44-808D-ADAADB2F9DACQ27687561-8E1EF1BD-F969-4BB2-A8E2-607D1D8D7D80Q28485166-EB81EA9D-BDD9-4DFE-8C3B-F1992707E674Q28485399-DFEC7C8C-8370-42FD-AAEB-4B1AEB6EAADCQ28730558-5ED50702-5C52-4E68-AEA6-5A578BAAD46CQ35760845-040704CF-0172-4B35-BA22-01F23C21AF89Q35837669-875614AE-881D-4B9B-AF27-59D15BEB537AQ36162690-21B08D7C-1D72-48DD-BB5A-2598531A41F9Q36472987-812F8D6C-A049-4351-8672-715EBE0F3524Q36490656-81F01EC6-9A31-4CDB-A161-7B09E6241749Q37286051-CC1D1BD9-C5DF-436E-A525-19270388FF87Q37423748-E9AFA755-2A06-4675-BDF3-3EE024664CD5Q37813152-44E06274-34A6-4120-A99F-3D0A76F2BDEBQ37827173-ECA42AF4-31AA-478A-9E24-A4A07FB2D56AQ38023238-06053F11-E739-4B80-AF97-021806675258Q38035044-06E8F58D-2C1E-48B9-9318-1A7246EB3A3EQ38095958-A1E34A37-1162-4494-BB7E-E50218D75705Q38125419-723FADFA-6B36-4917-9A8C-D7565730553BQ38166527-98BB1E20-7201-4777-9932-A8A49D065950Q38199919-767736F7-D2AF-40F6-920D-119238B4E336Q38255333-E146739E-4456-44A5-A121-5FD190D1941EQ38502737-F8F825BE-B339-483B-9ED6-5A4DBF34AAE3Q38807514-56164A70-511E-4EEB-A782-1B55F2B8760DQ39084975-06BACEDA-0207-4925-AB2F-03FE1033401EQ39277209-CF02DACC-5C8B-4EB5-893C-A14F206276B0Q39401044-DFB8AAC8-8C94-48F9-A7F6-649FDEF7974FQ39567800-0558802A-F01F-47C8-81E6-CF0CBD4E7C90Q39600656-E28C7465-5D87-4F08-8B15-524F03E931FAQ40297530-DD83BDC2-4F9A-4A2C-AE8C-F8F9D06BE799Q41470772-733B60D5-F506-498C-8B95-C44F1AFC5F3CQ42222764-9E4A250E-5B4A-436E-AC36-D597B3BF344CQ42554019-AF376995-AE31-4F3C-864B-169E0BE820C1Q42700000-02DF9DF6-7377-4DBA-85C1-5C4AC0EB40BEQ46665629-85E9AFF7-CEA1-4F79-BE4F-1F352ECE8507Q47699487-EA339275-A914-409F-B628-4DDAA36F490DQ53569824-BFD8F4C9-DAC9-4525-A572-02709B86E892
P2860
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh
2008年學術文章
@zh-hant
name
Signalling profile and antitum ...... VP-AUY922 in multiple myeloma.
@en
Signalling profile and antitum ...... VP-AUY922 in multiple myeloma.
@nl
type
label
Signalling profile and antitum ...... VP-AUY922 in multiple myeloma.
@en
Signalling profile and antitum ...... VP-AUY922 in multiple myeloma.
@nl
prefLabel
Signalling profile and antitum ...... VP-AUY922 in multiple myeloma.
@en
Signalling profile and antitum ...... VP-AUY922 in multiple myeloma.
@nl
P2093
P356
P1433
P1476
Signalling profile and antitum ...... NVP-AUY922 in multiple myeloma
@en
P2093
A Zöllinger
C García-Echeverría
C Unzicker
D Siegmund
J Schoepfer
M Chatterjee
M R Jensen
P2888
P304
P356
10.1038/LEU.2008.111
P577
2008-05-15T00:00:00Z